KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Short-term Investments (2016 - 2025)

Astrazeneca has reported Short-term Investments over the past 11 years, most recently at $90.0 million for Q4 2025.

  • Quarterly results put Short-term Investments at $90.0 million for Q4 2025, up 143.24% from a year ago — trailing twelve months through Dec 2025 was $90.0 million (up 143.24% YoY), and the annual figure for FY2025 was $90.0 million, up 143.24%.
  • Short-term Investments for Q4 2025 was $90.0 million at Astrazeneca, up from $37.0 million in the prior quarter.
  • Over the last five years, Short-term Investments for AZN hit a ceiling of $116.0 million in Q4 2023 and a floor of $37.0 million in Q4 2024.
  • Median Short-term Investments over the past 5 years was $87.0 million (2022), compared with a mean of $82.6 million.
  • Biggest five-year swings in Short-term Investments: plummeted 68.1% in 2024 and later surged 143.24% in 2025.
  • Astrazeneca's Short-term Investments stood at $83.0 million in 2021, then grew by 4.82% to $87.0 million in 2022, then soared by 33.33% to $116.0 million in 2023, then plummeted by 68.1% to $37.0 million in 2024, then surged by 143.24% to $90.0 million in 2025.
  • The last three reported values for Short-term Investments were $90.0 million (Q4 2025), $37.0 million (Q4 2024), and $116.0 million (Q4 2023) per Business Quant data.